利妥昔单抗时代原发难治性弥漫大B细胞淋巴瘤(DLBCL)接受挽救化疗并计划移植的结局
该研究回顾了82例适合移植的原发难治性DLBCL患者,接受挽救化疗并计划对化疗敏感者行高剂量治疗和自体干细胞移植(ASCT)。全部患者估计3年总生存率和无进展生存率分别为38%和29%,接受移植者分别为65%和60%。对初始诱导治疗达部分缓解(PR)者45%获长期缓解,而初始治疗后疾病稳定或进展者不足20%。
要点
- 全部82例原发难治性DLBCL患者估计3年总生存率和无进展生存率分别为38%和29%。
- 接受ASCT者估计3年总生存率和无进展生存率分别为65%和60%。
- 对初始诱导治疗达PR者45%获长期缓解,疾病稳定或进展者不足20%。
核心结论
- 以后续高剂量治疗和ASCT为意图的挽救化疗对部分原发难治性DLBCL患者仍是可行策略。
- 对 frontline 治疗达PR的患者尤其可能获益。
- 原发难治患者治愈的主要障碍是对挽救化疗的耐药,未来研究应着眼于提高该人群的缓解率。
研究设计与样本
- 回顾性分析82例适合移植的原发难治性DLBCL患者,接受挽救化疗并计划对达化疗敏感缓解者行高剂量治疗和ASCT。
主要发现
- 全部患者估计3年总生存率为38%,无进展生存率为29%。
- 接受干细胞移植者估计3年总生存率为65%,无进展生存率为60%。
- 对初始诱导治疗达PR者45%获长期缓解,初始治疗后疾病稳定或进展者不足20%获长期缓解。
临床怎么用
- 作者认为,以后续高剂量治疗和ASCT为意图的挽救化疗对部分原发难治性DLBCL患者仍是可行策略,尤其对 frontline 治疗达PR者。
- 作者建议未来研究应着眼于提高原发难治性DLBCL人群对挽救化疗的缓解率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, its role in those patients achieving less than a complete response to first-line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant-eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high-dose therapy and ASCT to patients achieving chemosensitive remission. The estimated 3-year overall and progression-free survival for all patients was 38% and 29%, respectively, and 65% and 60% respectively for patients proceeding to stem cell transplant. Long-term remission was achieved in 45% of patients achieving a partial response (PR) to initial induction therapy and <20% of patients with stable or progression of disease following initial therapy. These results suggest that salvage chemotherapy with the intent of subsequent high-dose therapy and ASCT remains a feasible strategy in certain patients with primary refractory DLBCL, particularly for those achieving a PR to frontline therapy. The primary barrier to curative therapy in patients with primary refractory disease is resistance to salvage therapy, and future studies should be aimed towards increasing the response rate in this population.
引用
- Vardhana SA, Sauter CS, Matasar MJ, et al. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2016. PMID: 27982423. doi:10.1111/bjh.14453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。